CG Oncology (CGON) Competitors

CG Oncology (NASDAQ:CGON) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership, community ranking and earnings.

Do analysts rate CGON or ROIV?

CG Oncology currently has a consensus price target of $63.88, indicating a potential upside of 131.94%. Roivant Sciences has a consensus price target of $17.10, indicating a potential upside of 60.26%. Given CG Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe CG Oncology is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do institutionals & insiders have more ownership in CGON or ROIV?

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has better valuation and earnings, CGON or ROIV?

Roivant Sciences has higher revenue and earnings than CG Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$684K	3,061.53	-$48.61M	N/A	N/A
Roivant Sciences	$122.59M	62.11	$4.35B	-$0.15	-71.13

Does the media favor CGON or ROIV?

In the previous week, Roivant Sciences had 7 more articles in the media than CG Oncology. MarketBeat recorded 17 mentions for Roivant Sciences and 10 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.91 beat Roivant Sciences' score of 0.66 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, CGON or ROIV?

CG Oncology has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Is CGON or ROIV more profitable?

Roivant Sciences has a net margin of -119.54% compared to CG Oncology's net margin of -10,642.98%. Roivant Sciences' return on equity of -14.05% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-10,642.98%	-18.97%	-15.36%
Roivant Sciences	-119.54%	-14.05%	-12.81%

Does the MarketBeat Community believe in CGON or ROIV?

Roivant Sciences received 31 more outperform votes than CG Oncology when rated by MarketBeat users. However, 92.00% of users gave CG Oncology an outperform vote while only 78.26% of users gave Roivant Sciences an outperform vote.

Company	Underperform	Outperform
CG Oncology	Outperform Votes 23 92.00%	Underperform Votes 2 8.00%
Roivant Sciences	Outperform Votes 54 78.26%	Underperform Votes 15 21.74%

Summary

Roivant Sciences beats CG Oncology on 9 of the 16 factors compared between the two stocks.